Oral GLP-1 Drug Orforglipron Shows Promising Weight Loss and Safety in First Human Trial
Orforglipron, an oral non-peptide GLP-1 receptor agonist, produced up to 5.4 kg weight loss in 4 weeks with a safety profile similar to injectable GLP-1 drugs in healthy participants.
Quick Facts
What This Study Found
In Part A (single dose, n=32), orforglipron showed dose-proportional pharmacokinetics with a half-life of 24.6–35.3 hours across doses of 0.3–6 mg. In Part B (multiple dose, n=60), 4 weeks of daily dosing with escalation to final target doses of 2–24 mg resulted in extended half-lives of 48.1–67.5 hours.
Participants receiving orforglipron lost up to 5.4 kg of body weight after 4 weeks compared to 2.4 kg with placebo (P < 0.05). Fasting glucose levels decreased across the treatment period, and gastric emptying was delayed on Day 28 — all consistent with GLP-1 receptor activation. The most common adverse events were gastrointestinal, similar to injectable GLP-1 receptor agonists.
Key Numbers
How They Did This
This was a Phase 1, double-blind, placebo-controlled, randomized study in healthy adults aged 18–65 with BMI 20–40 kg/m² and HbA1c below 6.5%. Part A tested single escalating doses (0.3–6 mg) in four cohorts. Part B tested 4 weeks of daily dosing with weekly dose escalation to four final target doses (2–24 mg). Safety, pharmacokinetics, body weight, fasting glucose, and gastric emptying were assessed.
Why This Research Matters
Current GLP-1 receptor agonists for weight loss and diabetes require injection, which limits adoption. An oral non-peptide alternative that works similarly could dramatically expand access to these treatments. Orforglipron's once-daily dosing without food or water restrictions also improves on existing oral GLP-1 options like oral semaglutide, which requires fasting.
The Bigger Picture
The development of oral non-peptide GLP-1 receptor agonists represents a potential paradigm shift in obesity and diabetes treatment. If orforglipron succeeds in later trials, it could make GLP-1-based therapy accessible to the millions of patients who are unwilling or unable to use injectable medications, while also simplifying treatment compared to oral semaglutide's strict dosing requirements.
What This Study Doesn't Tell Us
This was a Phase 1 study in healthy participants, not patients with diabetes or obesity. The treatment period was only 4 weeks, too short to assess long-term efficacy or safety. The sample size was small (92 total, split across multiple dose groups). Efficacy endpoints were exploratory, and larger Phase 2/3 trials in target patient populations are needed.
Questions This Raises
- ?How does orforglipron's weight loss efficacy compare to injectable semaglutide or tirzepatide over longer treatment periods?
- ?Will orforglipron maintain its favorable safety profile in patients with type 2 diabetes or obesity with comorbidities?
- ?Could the non-peptide structure of orforglipron offer advantages in terms of immunogenicity or long-term tolerability?
Trust & Context
- Key Stat:
- Up to 5.4 kg weight loss in 4 weeks Compared to 2.4 kg with placebo in healthy adults taking oral orforglipron, a non-peptide GLP-1 receptor agonist
- Evidence Grade:
- This is a Phase 1 clinical trial focused on safety and pharmacokinetics in healthy volunteers. While well-designed (randomized, double-blind, placebo-controlled), it was not powered for efficacy and used a short treatment duration in a non-target population.
- Study Age:
- Published in 2023, this Phase 1 data is part of the active clinical development program for orforglipron. Later-phase trials with efficacy data have since been reported.
- Original Title:
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- Published In:
- Diabetes, obesity & metabolism, 25(9), 2634-2641 (2023)
- Authors:
- Pratt, Edward(4), Ma, Xiaosu(4), Liu, Rong(5), Robins, Deborah, Haupt, Axel, Coskun, Tamer, Sloop, Kyle W, Benson, Charles
- Database ID:
- RPEP-07284
Evidence Hierarchy
Frequently Asked Questions
How is orforglipron different from semaglutide?
Unlike semaglutide, which is a peptide that must be injected or taken orally with strict fasting requirements, orforglipron is a non-peptide small molecule that can be taken as a daily pill without food or water restrictions. Both activate the same GLP-1 receptor.
Is orforglipron available yet?
As of this Phase 1 study, orforglipron is still in clinical development. It showed promising early results for weight loss and safety, but must complete Phase 2 and Phase 3 trials before it can be approved for clinical use.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07284APA
Pratt, Edward; Ma, Xiaosu; Liu, Rong; Robins, Deborah; Haupt, Axel; Coskun, Tamer; Sloop, Kyle W; Benson, Charles. (2023). Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.. Diabetes, obesity & metabolism, 25(9), 2634-2641. https://doi.org/10.1111/dom.15184
MLA
Pratt, Edward, et al. "Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.." Diabetes, 2023. https://doi.org/10.1111/dom.15184
RethinkPeptides
RethinkPeptides Research Database. "Orforglipron (LY3502970), a novel, oral non-peptide glucagon..." RPEP-07284. Retrieved from https://rethinkpeptides.com/research/pratt-2023-orforglipron-ly3502970-a-novel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.